Rocket Pharmaceuticals, Inc.
RCKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $34 | $43 | $36 | $37 |
| G&A Expenses | $18 | $25 | $28 | $25 |
| SG&A Expenses | $18 | $25 | $28 | $25 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $3 | $0 | $0 |
| Operating Expenses | $52 | $71 | $64 | $63 |
| Operating Income | -$52 | -$71 | -$64 | -$63 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $3 | $2 |
| Pre-Tax Income | -$50 | -$69 | -$61 | -$60 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$50 | -$69 | -$61 | -$60 |
| % Margin | – | – | – | – |
| EPS | -0.45 | -0.62 | -0.56 | -0.62 |
| % Growth | 27.4% | -10.7% | 9.7% | – |
| EPS Diluted | -0.45 | -0.62 | -0.56 | -0.62 |
| Weighted Avg Shares Out | 112 | 111 | 110 | 98 |
| Weighted Avg Shares Out Dil | 112 | 111 | 110 | 98 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $4 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $3 | $2 |
| EBITDA | -$47 | -$66 | -$58 | -$57 |
| % Margin | – | – | – | – |